Amarin Reports First Quarter 2014 Financial Results and Provides Update on Operations
May 09, 2014 07:00 ET
|
Amarin Corporation plc
BEDMINSTER, N.J. and DUBLIN, Ireland, May 9, 2014 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics...
Amarin to Report First Quarter 2014 Results and Host Conference Call on May 9, 2014
May 05, 2014 08:00 ET
|
Amarin Corporation plc
BEDMINSTER, N.J., and DUBLIN, Ireland, May 5, 2014 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of...
Amarin Announces Presentation of New MARINE and ANCHOR Post-Hoc Analyses at National Lipid Association Annual Scientific Sessions Showing Vascepa(R) Significantly Reduced Apolipoprotein C-III Levels
May 02, 2014 08:00 ET
|
Amarin Corporation plc
BEDMINSTER, N.J., and DUBLIN, Ireland, May 2, 2014 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of...
Amarin and Kowa Pharmaceuticals America, Inc. Announce U.S. Co-Promotion Agreement for Vascepa(R) (icosapent ethyl) Capsules
March 31, 2014 16:30 ET
|
Amarin Corporation plc
BEDMINSTER, N.J., DUBLIN, Ireland, and MONTGOMERY, Ala., March 31, 2014 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN) and Kowa Pharmaceuticals America, Inc., two biopharmaceutical companies...
Amarin Reports Fourth Quarter and Year-End 2013 Financial Results and Provides Update on Operations
February 27, 2014 16:01 ET
|
Amarin Corporation plc
BEDMINSTER, N.J. and DUBLIN, Ireland, Feb. 27, 2014 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late stage biopharmaceutical company focused on the commercialization and development of...
Amarin to Report Fourth Quarter and Year-End 2013 Results and Host Conference Call on February 27, 2014
February 24, 2014 06:00 ET
|
Amarin Corporation plc
BEDMINSTER, N.J. and DUBLIN, Ireland, Feb. 24, 2014 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of...
Amarin Announces FDA Award of Three-Year Exclusivity for Vascepa(R) (icosapent ethyl) Capsules
February 21, 2014 16:01 ET
|
Amarin Corporation plc
BEDMINSTER, N.J. and DUBLIN, Ireland, Feb. 21, 2014 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of...
Amarin to Present at the 2014 Leerink Global Healthcare Conference
February 06, 2014 06:30 ET
|
Amarin Corporation plc
BEDMINSTER, N.J., and DUBLIN, Ireland, Feb. 6, 2014 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of...
Amarin Announces Promotion of Aaron Berg to Senior Vice President, Marketing and Sales
February 04, 2014 06:00 ET
|
Amarin Corporation plc
BEDMINSTER, N.J., and DUBLIN, Ireland, Feb. 4, 2014 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of...
Amarin Announces FDA Review Division Response to ANCHOR SPA Agreement Reinstatement Request
January 21, 2014 01:00 ET
|
Amarin Corporation plc
Conference Call Set for 8:00 a.m. ET today
Amarin Plans Appeal to FDA Office Level, No FDA sNDA Action Expected During Appeal
BEDMINSTER, N.J., and DUBLIN, Ireland, Jan. 21, 2014 (GLOBE...